Achievement of a milestone in the global Phase III registration trial IZABRIGHT-Lung02 has triggered a USD 250 million near-term milestone payment to SystImmune, Inc. under its collaboration with Bristol Myers Squibb (AllSci Corp) - Sep 23, 2026 - "The payment represents the second USD 250 million tranche under the agreement, alongside an USD 800 million upfront payment received after the deal was signed in December 2023. IZABRIGHT-Lung02 is a BMS-led global registrational Phase III study evaluating izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjugate (ADC), in previously untreated patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC)....Biokin did not disclose the specific milestone event that triggered the payment, and the announcement included no clinical efficacy or safety data."
Financing • Non Small Cell Lung Cancer
|